HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Request Reprints Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (1) Citing Articles via Google Scholar Google Scholar Articles by McAleer, S. D. Articles by Sheikh, M. S. Search for Related Content PubMed PubMed Citation Articles by McAleer, S. D. Articles by Sheikh, M. S. Social Bookmarking                   What's this?

Pharmacokinetics and Safety of Ketorolac Following Single Intranasal and Intramuscular Administration in Healthy Volunteers

From Medeval Limited, a Division of ICON plc, Skelton House, Manchester Science Park, Lloyd Street North, Manchester, United Kingdom.

Ketorolac was administered to 15 healthy volunteers in a phase 1, single-dose, crossover, randomized study. Subjects received open-label randomized 15- and 30-mg intramuscular (IM) ketorolac and blinded randomized 15- and 30- mg intranasal (IN) ketorolac. The IN ketorolac was well tolerated; the only nasal symptoms were some instances of mild irritation. The IN ketorolac was rapidly and well absorbed (median t_max, 0.50-0.75 hours), and the half-life was approximately 5 to 6 hours, values that were similar to those following IM administration. Relative bioavailability of IN compared to IM administration at the same doses was approximately 67% to 75%. Dose proportionality was noted between the 15- and 30-mg IN and IM dose levels. Thus, IN ketorolac offers a therapeutic alternative to IM administration and may provide benefits in the clinical setting.

Key Words: Ketorolac • intranasal • intramuscular • pharmacokinetics • volunteers

Address for reprints: Oneeb Majid, ICON Development Solutions, Medeval Limited, Skelton House, Lloyd Street North, Manchester M15 6SH, UK.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				J. E. Moodie, C. R. Brown, E. J. Bisley, H. U. Weber, and L. Bynum The Safety and Analgesic Efficacy of Intranasal Ketorolac in Patients with Postoperative Pain Anesth. Analg., December 1, 2008; 107(6): 2025 - 2031. [Abstract] [Full Text] [PDF]